vs
Side-by-side financial comparison of SOLENO THERAPEUTICS INC (SLNO) and SMITH & WESSON BRANDS, INC. (SWBI). Click either name above to swap in a different company.
SMITH & WESSON BRANDS, INC. is the larger business by last-quarter revenue ($124.7M vs $66.0M, roughly 1.9× SOLENO THERAPEUTICS INC). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs 1.5%, a 37.9% gap on every dollar of revenue. SOLENO THERAPEUTICS INC produced more free cash flow last quarter ($43.5M vs $16.3M).
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
SLNO vs SWBI — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $66.0M | $124.7M |
| Net Profit | $26.0M | $1.9M |
| Gross Margin | 98.3% | 24.3% |
| Operating Margin | 33.5% | 3.3% |
| Net Margin | 39.4% | 1.5% |
| Revenue YoY | — | -3.9% |
| Net Profit YoY | 134.0% | -53.6% |
| EPS (diluted) | $0.47 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $124.7M | ||
| Q3 25 | $66.0M | $85.1M | ||
| Q2 25 | $32.7M | $140.8M | ||
| Q1 25 | — | $115.9M | ||
| Q4 24 | — | $129.7M | ||
| Q3 24 | — | $88.3M | ||
| Q2 24 | — | $159.1M | ||
| Q1 24 | — | $137.5M |
| Q4 25 | — | $1.9M | ||
| Q3 25 | $26.0M | $-3.4M | ||
| Q2 25 | $-4.7M | $8.6M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | — | $-1.9M | ||
| Q2 24 | — | $27.9M | ||
| Q1 24 | — | $7.9M |
| Q4 25 | — | 24.3% | ||
| Q3 25 | 98.3% | 25.9% | ||
| Q2 25 | 97.9% | 28.8% | ||
| Q1 25 | — | 24.1% | ||
| Q4 24 | — | 26.6% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | — | 35.5% | ||
| Q1 24 | — | 28.7% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | 33.5% | -3.5% | ||
| Q2 25 | -20.0% | 9.3% | ||
| Q1 25 | — | 4.1% | ||
| Q4 24 | — | 5.8% | ||
| Q3 24 | — | -1.7% | ||
| Q2 24 | — | 17.4% | ||
| Q1 24 | — | 8.2% |
| Q4 25 | — | 1.5% | ||
| Q3 25 | 39.4% | -4.0% | ||
| Q2 25 | -14.4% | 6.1% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | -2.1% | ||
| Q2 24 | — | 17.5% | ||
| Q1 24 | — | 5.7% |
| Q4 25 | — | $0.04 | ||
| Q3 25 | $0.47 | $-0.08 | ||
| Q2 25 | $-0.09 | $0.19 | ||
| Q1 25 | — | $0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $0.60 | ||
| Q1 24 | — | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $498.9M | $22.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $494.8M | $363.2M |
| Total Assets | $599.9M | $548.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $22.4M | ||
| Q3 25 | $498.9M | $18.0M | ||
| Q2 25 | $286.8M | $25.2M | ||
| Q1 25 | — | $26.7M | ||
| Q4 24 | — | $39.1M | ||
| Q3 24 | — | $35.5M | ||
| Q2 24 | — | $60.8M | ||
| Q1 24 | — | $47.4M |
| Q4 25 | — | $363.2M | ||
| Q3 25 | $494.8M | $364.4M | ||
| Q2 25 | $240.1M | $372.5M | ||
| Q1 25 | — | $366.9M | ||
| Q4 24 | — | $371.5M | ||
| Q3 24 | — | $380.0M | ||
| Q2 24 | — | $399.9M | ||
| Q1 24 | — | $376.4M |
| Q4 25 | — | $548.6M | ||
| Q3 25 | $599.9M | $554.6M | ||
| Q2 25 | $332.3M | $559.6M | ||
| Q1 25 | — | $578.9M | ||
| Q4 24 | — | $587.4M | ||
| Q3 24 | — | $571.3M | ||
| Q2 24 | — | $577.4M | ||
| Q1 24 | — | $570.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.5M | $27.3M |
| Free Cash FlowOCF − Capex | $43.5M | $16.3M |
| FCF MarginFCF / Revenue | 65.8% | 13.1% |
| Capex IntensityCapex / Revenue | 0.0% | 8.8% |
| Cash ConversionOCF / Net Profit | 1.67× | 14.22× |
| TTM Free Cash FlowTrailing 4 quarters | — | $21.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $27.3M | ||
| Q3 25 | $43.5M | $-8.1M | ||
| Q2 25 | $-12.6M | $40.8M | ||
| Q1 25 | — | $-9.8M | ||
| Q4 24 | — | $-7.4M | ||
| Q3 24 | — | $-30.8M | ||
| Q2 24 | — | $43.7M | ||
| Q1 24 | — | $25.2M |
| Q4 25 | — | $16.3M | ||
| Q3 25 | $43.5M | $-12.4M | ||
| Q2 25 | $-12.6M | $33.5M | ||
| Q1 25 | — | $-16.1M | ||
| Q4 24 | — | $-10.7M | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $38.2M | ||
| Q1 24 | — | $7.0M |
| Q4 25 | — | 13.1% | ||
| Q3 25 | 65.8% | -14.6% | ||
| Q2 25 | -38.6% | 23.8% | ||
| Q1 25 | — | -13.9% | ||
| Q4 24 | — | -8.3% | ||
| Q3 24 | — | -40.2% | ||
| Q2 24 | — | 24.0% | ||
| Q1 24 | — | 5.1% |
| Q4 25 | — | 8.8% | ||
| Q3 25 | 0.0% | 5.0% | ||
| Q2 25 | 0.0% | 5.2% | ||
| Q1 25 | — | 5.4% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 5.3% | ||
| Q2 24 | — | 3.5% | ||
| Q1 24 | — | 13.2% |
| Q4 25 | — | 14.22× | ||
| Q3 25 | 1.67× | — | ||
| Q2 25 | — | 4.73× | ||
| Q1 25 | — | -4.68× | ||
| Q4 24 | — | -1.63× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.57× | ||
| Q1 24 | — | 3.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
